Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Apr 24, 2021; 12(4): 249-261
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249

Table 2 Surgical outcomes

	PET-CMR, n = 22	Non-PET-CMR, n = 36	P value
Esophagectomy procedures
Subtotal	20	32	0.31
Cervical	1	0
Pharyngeal laryngeal	1	4
LN dissection
Cervical	1	2	0.89
2 fields	5	10
3 fields	16	24
Harvested LN¹	72 ± 7	73 ± 5	0.91
Blood loss in mL¹	559 ± 219	836 ± 540	0.026
OP time in min¹	527 ± 105	580 ± 121	0.092
Curability
R0	22	29	0.027
R1	0	7
Intraoperative complication
Bronchus injury	1	1	0.72
Postoperative complication
All	14	22	0.85
Anastomotic leakage²	1	1	0.72
Anastomotic stenosis²	2	3	0.92
Recurrent nerve palsy²	7	12	0.91
Respiratory²	3	8	0.42
Others²	2	3	0.92
Surgical mortality	0	0	-

¹mean ± SD.

²Clavien-Dindo Classification ≥ 3.

LN: Lymph node; OP: Operation; PET-CMR: Positron emission tomography-complete metabolic response.

Citation: Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.249

Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261 [PMID: 33959478 DOI: 10.5306/wjco.v12.i4.249]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.